NCT07502521

Dexrazoxane to Protect Against Hemorrhagic STEMI

A Phase IIa, Prospective Placebo-Controlled Trial Evaluating the Efficacy of Dexrazoxane in Mitigating Intramyocardial Hemorrhage and Infarct Expansion in Acute STEMI

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Rohan Dharmakumar · Academic / Other
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

This Phase Ila trial evaluates whether the intravenous administration of Dexrazoxane can reduce permanent heart muscle damage in patients undergoing standard stent procedures (PCI) for a severe heart attack (STEMI).

Conditions

• Acute Myocardial Infarction (AMI)

Interventions

Type	Name	Description
DRUG	Dexrazoxane	Intravenous infusion administered adjunctively to primary PCI
DRUG	Normal Saline	Visually identical placebo infusion (Normal Saline 0.9% NaCl) of similar volume administered adjunctively to primary percutaneous coronary intervention (PCI). Administered at four timepoints: emergency room (pre-PCI), 4 hours, 8 hours, and 12 hours post-primary PCI, identical in appearance, volume, and schedule to the investigational product.

Timeline

• Start date: 2025-08-30
• Primary completion: 2026-02-15
• Completion: 2026-03-16
• First posted: 2026-03-31
• Last updated: 2026-04-13

Locations

1 site across 1 country: India